ANI Pharmaceuticals' stock surged 8.08% in the pre-market trading session on Friday, following the company's impressive fourth-quarter 2024 earnings report that exceeded Wall Street's expectations.
The pharmaceutical company reported adjusted earnings per share of $1.63, significantly beating the analyst consensus estimate of $1.44. Moreover, ANI Pharmaceuticals' quarterly sales of $190.57 million surpassed the estimated $175.37 million, representing a 44.75% year-over-year increase.
The strong financial results, driven by robust sales growth and better-than-expected profitability, have fueled investor confidence in ANI Pharmaceuticals' prospects, leading to the pre-market stock rally.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。